Immunovaccine has signed a collaborative agreement with the National Cancer Institute (NCI) in Maryland, US. The research collaboration involves formulating NCI’s cancer vaccine antigens in DepoVax, Immunovaccine’s vaccine enhancement system.
DepoVax is a vaccine enhancement and delivery platform which has demonstrated ability to enhance the immunogenicity of antigens by creating a strong depot at the site of immunization.
Immunovaccine has previously shown eradication of tumors in three animal models.
Reportedly, the research team at Immunovaccine will be collaborating with NCI investigator Jeffrey Schlom, head of the Immunotherapeutics group and chief of the Laboratory of Tumor Immunology & Biology.
Marc Mansour, vice president of R&D at Immunovaccine, said: “We look forward to seeing how our enhanced DepoVax delivery system improves immune responses to treat cancer.”